Gastroparesis and GLP-1s: Clinical Risk Assessment

Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Gastroparesis and GLP-1 medications present a complex clinical intersection requiring careful evaluation before treatment initiation. Delayed gastric emptying and GLP-1-mediated slowing of GI motility may compound risk in susceptible patients, making pre-treatment screening essential.

PlexusDx advocates for precision-guided assessment: understanding your individual risk profile—including genetic predispositions in metabolic and GI pathways—supports more informed conversations with your healthcare provider about whether GLP-1 therapy is appropriate for your clinical situation.

Defining Gastroparesis and Its Relationship to GLP-1 Mechanism

Gastroparesis is a condition characterized by delayed gastric emptying without mechanical obstruction. GLP-1 receptor agonists intentionally slow gastric motility as part of their appetite-suppression mechanism, creating potential concern for symptom overlap or exacerbation in predisposed individuals.

The incidence of symptomatic gastroparesis is approximately 1–4 per 100,000 person-years, but subclinical delayed emptying may be more common. Understanding whether you have baseline GI dysmotility before starting GLP-1 therapy is a key screening step your provider should assess.

Clinical Risk Factors and Pre-Treatment Screening Markers

Several risk factors increase gastroparesis susceptibility: diabetes (especially longstanding type 1), vagal neuropathy, autoimmune gastritis, medications affecting motility, and prior gastric surgery. Your medical history should be reviewed comprehensively before GLP-1 initiation to identify these predisposing factors.

Risk Factor Category	Clinical Significance for GLP-1 Use
Diabetes duration and type	Type 1 and longstanding type 2 carry higher intrinsic gastroparesis risk; GLP-1 may compound delay
Neuropathy presence	Autonomic or peripheral neuropathy suggests GI dysfunction risk; baseline motility assessment may be warranted
Medication history	Anticholinergics, opioids, and some antiemetics worsen motility; drug interactions must be evaluated
GI surgical history	Prior gastric banding, bypass, or fundoplication alters anatomy and motility response to GLP-1

Diagnostic Approaches and Evidence-Based Assessment

If gastroparesis is suspected, gastric emptying scintigraphy (GES) is the gold-standard diagnostic test. It measures the proportion of meal remaining in the stomach at fixed intervals; delayed emptying at 2 hours and 4 hours confirms diagnosis. Your provider may order this test before GLP-1 initiation if risk is elevated.

Antral dysmotility and reduced antral contractions on GES correlate with GLP-1 symptom risk. Some providers also use wireless capsule motility studies or high-resolution gastric manometry in complex cases. Baseline diagnostic clarity enables more individualized dosing and monitoring strategies if GLP-1 therapy proceeds.

Safety Monitoring, Dose Adjustment, and Who Should Avoid GLP-1 Therapy

Patients with confirmed gastroparesis are generally counseled to avoid GLP-1 medications, or to use them only under intensive specialist co-management (gastroenterology plus endocrinology). If gastroparesis is subclinical or mild, some providers may proceed with cautious dose titration and frequent symptom monitoring for nausea, vomiting, and early satiety.

Absolute contraindications include symptomatic gastroparesis, history of GLP-1-induced acute pancreatitis, or severe GI dysmotility syndromes. Your provider should discuss whether alternative weight-management strategies—behavioral, dietary, or pharmacologic (non-GLP-1 agents)—are safer options for your individual clinical profile.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test examines predispositions in peptide metabolism pathways, including GLP1R and MC4R variants, which may help provide context for individual metabolic and GI responsiveness. Genetic data alone does not predict gastroparesis risk, but can support a more comprehensive clinical picture when interpreted with your provider.

The Precision Peptide Genetic Test reveals variants in GLP-1 receptor signaling (GLP1R rs6923761) and metabolic control (MC4R rs17782313, FTO rs9939609) that may influence how your body responds to GLP-1 mechanisms. These predispositions should be interpreted alongside your clinical history, family GI disease background, and diagnostic screening results.

Understanding your genetic predispositions in peptide pathways can support a more informed conversation with your healthcare team about GLP-1 eligibility, optimal dosing, and whether alternative therapies may be better suited to your risk profile. This precision data supports shared decision-making, not treatment decisions made in isolation.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.